MacroGenics (NASDAQ:MGNX) VP Sells $129,085.75 in Stock

MacroGenics, Inc. (NASDAQ:MGNX) VP Jeffrey Stuart Peters sold 31,105 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $4.15, for a total transaction of $129,085.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

MacroGenics Price Performance

Shares of MacroGenics stock opened at $4.10 on Friday. MacroGenics, Inc. has a fifty-two week low of $1.29 and a fifty-two week high of $5.08. The firm has a market capitalization of $261.17 million, a P/E ratio of -18.64 and a beta of 1.20. The company’s 50 day moving average price is $4.24 and its two-hundred day moving average price is $3.46.

MacroGenics (NASDAQ:MGNX) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.39. The firm had revenue of $32.83 million for the quarter, compared to analysts’ expectations of $59.14 million. MacroGenics had a negative net margin of 8.70% and a negative return on equity of 109.26%. On average, analysts expect that MacroGenics, Inc. will post -1.48 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on MGNX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MacroGenics in a report on Wednesday, August 5th. B. Riley Financial lifted their price target on MacroGenics from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, August 17th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, MacroGenics currently has an average rating of “Hold” and a consensus price target of $6.33.

Institutional Trading of MacroGenics

Several institutional investors have recently modified their holdings of MGNX. R Squared Ltd acquired a new stake in MacroGenics in the fourth quarter valued at $26,000. Legal & General Group Plc acquired a new position in MacroGenics during the 2nd quarter worth about $28,000. Engineers Gate Manager LP acquired a new position in MacroGenics during the 2nd quarter worth about $28,000. Walleye Capital LLC bought a new stake in shares of MacroGenics in the 2nd quarter valued at about $30,000. Finally, Cresset Asset Management LLC grew its position in shares of MacroGenics by 52.3% in the 2nd quarter. Cresset Asset Management LLC now owns 26,720 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 9,172 shares during the last quarter. Institutional investors own 96.89% of the company’s stock.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics’ research platform are its ADAPTIR and Trident bispecific antibody technologies.